The pharmaceutical talent conversation focuses heavily on visible categories. Drug discovery scientists. Manufacturing operators. Clinical research professionals. Regulatory affairs specialists. Each of these gets significant industry attention, formal pipeline development through university partnerships, and substantive media coverage of the talent shortage.
Formulation science gets less attention. It also has one of the thinnest, most structurally underdeveloped talent pipelines in pharmaceutical manufacturing.
This matters because formulation science sits at the foundation of every drug product. The formulation scientist is the person who determines whether a promising molecule can actually be manufactured at scale, delivered to patients in a stable form, and produced economically. Without formulation expertise, even the most promising drug candidates remain laboratory curiosities. With deep formulation expertise, ordinary molecules become viable medicines.
The industry is now demanding more formulation expertise than the talent pipeline is producing. The gap has been widening for 20 years, and the consequences are now arriving.
A peer-reviewed perspective published in the European Journal of Pharmaceutical Sciences in 2026 by Maclean and colleagues documented the workforce trajectory directly. Traditional pharmaceutical roles, including formulation scientists, analytical chemists, and manufacturing operators, are expanding to incorporate digital tools, AI-enabled formulation development, and cross-disciplinary collaboration. The university-level pipeline, the authors noted, has not kept pace with these changing skill requirements.
The authors are not alone. The Pharmaceutical Research and Manufacturers of America projected as far back as 2017 that the U.S. would need to hire 3.4 million life sciences and pharma employees by 2025, but that 60% of those positions would be vacant due to skills shortages and inadequate education policies. By 2020, McKinsey research concluded that 80% of pharma manufacturing companies were reporting a skills mismatch.
The formulation segment of this broader talent challenge has specific characteristics that make it harder to address through normal market mechanisms.
Formulation sits at an awkward intersection in pharmaceutical career paths. It is more applied than discovery chemistry but more scientific than manufacturing operations. Most pharmaceutical sciences graduates have historically flowed toward higher-visibility career tracks: drug discovery, clinical development, or analytical method development. The formulation track has been less prestigious within academic pharmaceutical sciences departments, less well-compensated relative to its technical complexity, and less well-developed as a structured career path inside major pharma organizations.
The result is that the formulation talent pool entering 2026 is small, aging, and structurally undersupplied relative to the demand pharma manufacturing is now placing on it.
Four forces are simultaneously increasing the pharmaceutical industry’s demand for formulation and excipient expertise.
Biologics formulation complexity. The biologics market is on a long-term growth trajectory that will continue through 2035. Per Mordor Intelligence’s January 2026 analysis, global biologics revenue is forecast to exceed $679.56 billion by 2030. Biologics formulation requires specialized expertise in protein stability, lyophilization, aseptic compatibility, and increasingly in concentrated formulation for subcutaneous and self-administered delivery. Small molecule formulation expertise does not transfer directly. The biologics formulation skill set must be developed deliberately.
Complex generics and biosimilars. The patent cliff through 2030 is expanding the biosimilar and complex generic opportunity. Companies pursuing approval through the BPCIA 351(k) pathway require formulation expertise to demonstrate comparability to reference products. The formulation work in biosimilar development is substantively different from traditional generic drug development, and the talent pool that can do this work credibly is small.
Personalized medicine and novel modalities. Cell therapies, gene therapies, antibody-drug conjugates, oligonucleotides, and other emerging modalities each require formulation expertise that often does not exist in traditional formulation scientist training. The educational pipeline has not yet adapted to produce formulation scientists with native fluency in these modalities at scale, which means the industry is competing for a small pool of formulation scientists who built that fluency through on-the-job experience at the small number of companies pioneering each modality.
Patient-centric delivery formats. Per Precision Reports’ April 2026 industry analysis, 75% adoption of prefilled syringes is driving formulation demand for novel container compatibility, viscosity management, and silicone oil interactions. Growing demand for oral dissolving formulations, depot injectables, novel inhalation delivery, and combination products extends the formulation expertise requirement beyond traditional vial-based approaches.
Each of these demand drivers individually would stress a normal talent pipeline. The fact that all four are happening simultaneously is creating the structural shortage the industry is now beginning to recognize.
The pharmaceutical industry has made meaningful progress addressing some workforce challenges. Biomanufacturing apprenticeship programs through community colleges. The Boston Life Sciences Workforce Development Initiative. Industry-academic partnerships at North Carolina, Pennsylvania, and other state universities. The WHO Biomanufacturing Workforce Training Initiative.
These programs are real and matter. They are also concentrated on biomanufacturing operations, fill-finish, and quality control. Formulation science has received much less workforce development attention, in part because it is a smaller specialty and in part because formulation expertise traditionally develops through extended apprenticeship inside pharma operations rather than through formal academic-industry partnerships.
The practical implication is that the workforce development infrastructure being built for the broader pharmaceutical industry will not solve the formulation talent problem. Solving the formulation talent problem requires deliberate investment in formulation-specific pipeline development, and most pharma organizations have not made that investment.
The pharma manufacturers and CDMOs successfully building formulation capability share four characteristics.
They run formal capability audits. A capability audit identifies the specific formulation expertise the organization currently has, the expertise it needs against pipeline complexity over the next five years, and the gap between the two. Most audits reveal a formulation function staffed thinly relative to pipeline complexity, with key expertise concentrated in a small number of senior individuals whose retirement or departure would create immediate operational risk.
They invest in cross-training pathways. Mid-career analytical chemists and process engineers represent an underused source of formulation talent. With structured 18 to 24 month development programs, individuals from adjacent disciplines can be developed into formulation roles with sufficient depth to take on substantive program work. The companies running these programs are building formulation capability more reliably than companies depending exclusively on external recruiting.
They build university partnerships specifically focused on formulation. General pharmaceutical sciences partnerships do not necessarily produce formulation specialists. Targeted partnerships with the small number of U.S. universities that maintain strong industrial pharmacy programs, with deliberate internship and fellowship pathways, produce more reliable formulation talent than generic biotech recruiting at the same universities.
They retain senior formulation talent at multiples of historical compensation norms. The cost of losing a senior formulation scientist is measured in program timeline slippage, regulatory submission risk, and lost institutional knowledge. Companies that calibrate retention investment to that actual cost, rather than to historical compensation benchmarks, hold senior formulation talent meaningfully longer than their peers.
The formulation talent shortage is not going to resolve through normal market correction. The university pipeline has been narrow for two decades. The senior formulation scientist demographic skews older. The demand drivers are accelerating. The conventional pharma response of competing harder for the same external candidates is not solving the problem.
Three priorities belong on the next operations agenda for any pharma manufacturer or CDMO with formulation-dependent programs.
First, run a formal formulation capability audit. The output should identify the specific formulation expertise the organization holds today, the expertise required against pipeline complexity over the next five years, and the gap between the two. The audit becomes the foundation for everything else.
Second, evaluate whether internal cross-training pathways exist to develop formulation depth from adjacent talent (analytical chemistry, process engineering, pharmaceutical sciences PhDs in adjacent specialties). If they do not, building them is multi-year infrastructure investment that needs to start now.
Third, examine retention strategy for senior formulation talent against the actual cost of losing them. The retention investment for a senior formulation scientist with biologics or complex generics expertise should be calibrated to the program risk associated with their departure, not to compensation benchmarks designed for general pharma scientific talent.
The formulation talent gap is going to grow before it shrinks. The companies that build formulation capability deliberately during the next five years will own meaningful competitive advantage in product development through the next decade. The companies that treat formulation as a normal hiring category will spend the next decade explaining why programs slipped, products faced stability issues, and regulatory submissions encountered formulation-related delays.
RX2 Solutions is a workforce solutions firm specializing in HR outsourcing, executive search, and strategic staffing. We partner with organizations to build high-performing teams through customized talent strategies, leadership placement, and scalable workforce solutions.
📞 Phone: 610.340.3490
📧 Email: info@rx2solutions.com
🌐 Website: www.rx2solutions.com
RX2 Solutions
A Respectfully Professional People Company